These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 31494110)

  • 21. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
    Khakde S; Jawaid H; Yasmin F; Binte Ali M; Rehman A
    Minerva Endocrinol (Torino); 2022 Sep; 47(3):344-357. PubMed ID: 33331740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minireview: are SGLT2 inhibitors heart savers in diabetes?
    Grubić Rotkvić P; Cigrovski Berković M; Bulj N; Rotkvić L
    Heart Fail Rev; 2020 Nov; 25(6):899-905. PubMed ID: 31410757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
    Ojha U; Reyes L; Eyenga F; Oumbe D; Watkowska J; Saint-Jacques H
    Am J Cardiovasc Drugs; 2022 Jan; 22(1):35-46. PubMed ID: 34189716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!
    Clark KAA
    Postgrad Med J; 2023 Sep; 99(1176):1052-1057. PubMed ID: 37001168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of perioperative discontinuation of SGLT2 inhibitors.
    Oosterom-Eijmael MJP; Hermanides J; van Raalte DH; Hulst AH
    Br J Anaesth; 2024 Aug; 133(2):239-240. PubMed ID: 38834489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome trial data on sodium glucose cotransporter-2 inhibitors: Putting clinical benefits and risks in perspective.
    Chiang B; Chew DP; De Pasquale CG
    Int J Cardiol; 2022 Feb; 349():96-98. PubMed ID: 34920045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SGLT2 inhibitors: A new era for our patients].
    Halimi JM
    Nephrol Ther; 2021 Jun; 17(3):143-148. PubMed ID: 33773943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
    Mordi IR; Lang CC
    Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.